Dong-A ST out-licensed its diabetes treatment to a Russian company, Reropharm
Dong-A ST(President and CEO Chan-il Park) announced on the 20th that it has established an out-licensing contract of the new self-developed diabetes treatment, ‘Evogliptin(code name: DA-1229),’ with a Russian company, Geropharm LLC.
Under the contract, Dong-A ST will receive down payment and lic...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
